Literature DB >> 29936631

Increased plasma xanthine oxidoreductase activity deteriorates coronary artery spasm.

Ken Watanabe1, Tetsuro Shishido2, Yoichiro Otaki1, Tetsu Watanabe1, Takayuki Sugai1, Taku Toshima1, Tetsuya Takahashi1, Miyuki Yokoyama1, Daisuke Kinoshita1, Takayo Murase3, Takashi Nakamura4, Masahiro Wanezaki1, Harutoshi Tamura1, Satoshi Nishiyama1, Hiroki Takahashi1, Takanori Arimoto1, So Yamauchi1, Tamon Yamanaka1, Takuya Miyamoto1, Isao Kubota1, Masafumi Watanabe1.   

Abstract

Increased reactive oxygen species (ROS) contributes to the development of endothelial dysfunction, which is involved in coronary artery spasm (CAS). Xanthine oxidoreductase (XOR) plays a pivotal role in producing both uric acid and ROS. However, the association between plasma XOR activity and CAS has not been elucidated. The aim of this study was to investigate whether plasma XOR activity is associated with CAS. We measured XOR activity in 104 patients suspected for CAS, who presented without significant coronary artery stenosis and underwent intracoronary acetylcholine provocation tests. CAS was provoked in 44 patients and they had significantly higher XOR activity as compared with those without CAS. The patients were divided into three groups based on the XOR activity. The prevalence rate of CAS was increased with increasing XOR activity. A multivariate logistic regression analysis showed that the 3rd tertile group exhibited a higher incidence of CAS as compared with the 1st tertile group [odds ratio (OR) 6.9, P = 0.001) and the 2nd tertile group (OR 3.2, P = 0.033) after adjustment for conventional CAS risk factors, respectively. The C index was significantly improved by the addition of XOR activity to the baseline model based on CAS risk factors. Furthermore, the 3rd tertile group had the highest incidence of severe spasm defined as total obstruction, flow-limiting stenosis, diffuse spasm, multivessel spasm, and/or lethal arrhythmia. This is a first report to elucidate the association of plasma XOR activity with CAS. Increased plasma XOR activity is significantly associated with CAS.

Entities:  

Keywords:  Coronary artery spasm; Reactive oxygen species; Uric acid; Xanthine oxidoreductase

Mesh:

Substances:

Year:  2018        PMID: 29936631     DOI: 10.1007/s00380-018-1207-4

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  35 in total

1.  Relation of serum uric acid and body mass index to mortality in high-risk patients with established coronary artery disease: a report from the ET-CHD registry, 1997-2006.

Authors:  Yi-Hwei Li; Gen-Min Lin; Chin-Lon Lin; Ji-Hung Wang; Yu-Jung Chen; Chih-Lu Han
Journal:  J Cardiol       Date:  2013-07-06       Impact factor: 3.159

2.  High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.

Authors:  Jacob George; Elaine Carr; Justine Davies; J J F Belch; Allan Struthers
Journal:  Circulation       Date:  2006-11-27       Impact factor: 29.690

3.  Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation.

Authors:  Stephan Spiekermann; Ulf Landmesser; Sergey Dikalov; Martin Bredt; Graciela Gamez; Helma Tatge; Nina Reepschläger; Burkhard Hornig; Helmut Drexler; David G Harrison
Journal:  Circulation       Date:  2003-03-18       Impact factor: 29.690

4.  Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide.

Authors:  R Radi; J S Beckman; K M Bush; B A Freeman
Journal:  J Biol Chem       Date:  1991-03-05       Impact factor: 5.157

5.  Acetylcholine-Provoked Coronary Spasm at Site of Significant Organic Stenosis Predicts Poor Prognosis in Patients With Coronary Vasospastic Angina.

Authors:  Masanobu Ishii; Koichi Kaikita; Koji Sato; Tomoko Tanaka; Koichi Sugamura; Kenji Sakamoto; Yasuhiro Izumiya; Eiichiro Yamamoto; Kenichi Tsujita; Megumi Yamamuro; Sunao Kojima; Hirofumi Soejima; Seiji Hokimoto; Kunihiko Matsui; Hisao Ogawa
Journal:  J Am Coll Cardiol       Date:  2015-09-08       Impact factor: 24.094

6.  Impact of high-density lipoprotein cholesterol level in patients with variant angina pectoris.

Authors:  Yasuo Sugano; Toshihisa Anzai; Takashi Yagi; Shigetaka Noma
Journal:  Int J Cardiol       Date:  2008-12-24       Impact factor: 4.164

7.  Uric acid secretion from adipose tissue and its increase in obesity.

Authors:  Yu Tsushima; Hitoshi Nishizawa; Yoshihiro Tochino; Hideaki Nakatsuji; Ryohei Sekimoto; Hirofumi Nagao; Takashi Shirakura; Kenta Kato; Keiichiro Imaizumi; Hiroyuki Takahashi; Mizuho Tamura; Norikazu Maeda; Tohru Funahashi; Iichiro Shimomura
Journal:  J Biol Chem       Date:  2013-08-02       Impact factor: 5.157

Review 8.  Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme.

Authors:  Maria Giulia Battelli; Andrea Bolognesi; Letizia Polito
Journal:  Biochim Biophys Acta       Date:  2014-05-29

Review 9.  Xanthine oxidoreductase-catalyzed reactive species generation: A process in critical need of reevaluation.

Authors:  Nadiezhda Cantu-Medellin; Eric E Kelley
Journal:  Redox Biol       Date:  2013-06-10       Impact factor: 11.799

10.  Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations.

Authors:  Judith A Finegold; Perviz Asaria; Darrel P Francis
Journal:  Int J Cardiol       Date:  2012-12-04       Impact factor: 4.164

View more
  6 in total

1.  Urinary 2,8-dihydroxyadenine excretion in patients with adenine phosphoribosyltransferase deficiency, carriers and healthy control subjects.

Authors:  Hrafnhildur L Runolfsdottir; Runolfur Palsson; Unnur A Thorsteinsdottir; Olafur S Indridason; Inger M Sch Agustsdottir; G Steinunn Oddsdottir; Margret Thorsteinsdottir; Vidar O Edvardsson
Journal:  Mol Genet Metab       Date:  2019-05-28       Impact factor: 4.797

2.  Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction.

Authors:  Ken Watanabe; Tetsu Watanabe; Yoichiro Otaki; Tetsuro Shishido; Takayo Murase; Takashi Nakamura; Shigehiko Kato; Harutoshi Tamura; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Masafumi Watanabe
Journal:  ESC Heart Fail       Date:  2020-05-20

3.  Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes.

Authors:  Tomoko Okuyama; Jun Shirakawa; Takashi Nakamura; Takayo Murase; Daisuke Miyashita; Ryota Inoue; Mayu Kyohara; Yu Togashi; Yasuo Terauchi
Journal:  Sci Rep       Date:  2021-02-12       Impact factor: 4.379

4.  Gender Differences in the Impact of Plasma Xanthine Oxidoreductase Activity on Coronary Artery Spasm.

Authors:  Ken Watanabe; Tetsu Watanabe; Yoichiro Otaki; Takayo Murase; Takashi Nakamura; Shigehiko Kato; Harutoshi Tamura; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Masafumi Watanabe
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

5.  Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study.

Authors:  Masami Nishino; Yasuyuki Egami; Hitoshi Nakamura; Kohei Ukita; Akito Kawamura; Yutaka Matsuhiro; Koji Yasumoto; Masaki Tsuda; Akihiro Tanaka; Naotaka Okamoto; Yasuharu Matsunaga-Lee; Masamichi Yano; Ryu Shutta; Jun Tanouchi
Journal:  Health Sci Rep       Date:  2022-03-22

6.  Time-dependent changes in plasma xanthine oxidoreductase during hospitalization of acute heart failure.

Authors:  Hirotake Okazaki; Akihiro Shirakabe; Masato Matsushita; Yusaku Shibata; Shota Shigihara; Tomofumi Sawatani; Kenichi Tani; Kazutaka Kiuchi; Yusuke Otsuka; Takayo Murase; Takashi Nakamura; Nobuaki Kobayashi; Noritake Hata; Kuniya Asai; Wataru Shimizu
Journal:  ESC Heart Fail       Date:  2020-12-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.